Baidu
map

JCLA:血管内皮生长因子+405C / G多态性对冠状动脉疾病长期预后及严重程度的影响

2017-07-24 MedSci MedSci原创

已经有关于血管内皮生长因子(VEGF)基因的遗传变异与动脉粥样硬化的风险之间的关联的假说。本研究旨在评估rs2010963(+405 C / G)多态性与伊朗队列中冠状动脉疾病(CAD)的出现,严重程度和结局之间的关系。

近日,国际杂志 《Journal of Clinical Laboratory Analysis》上在线发表一项关于血管内皮生长因子+405C / G多态性对冠状动脉疾病长期预后及严重程度的影响的研究。

已经有关于血管内皮生长因子(VEGF)基因的遗传变异与动脉粥样硬化的风险之间的关联的假说。本研究旨在评估rs2010963+405 C / G)多态性与伊朗队列中冠状动脉疾病(CAD)的出现,严重程度和结局之间的关系。

研究使用TaqMan实时PCR方法,对520名患者进行了VEGF rs2010963多态性的基因分型,其中包括347名根据血管造影报告记录的冠状动脉疾病患者和173例正常冠状动脉的患者。最后,对484例受试者随访了5年并记录心血管相关结局。

研究发现VEGF rs2010963多态性的C等位基因与CAD的风险增加相关,也与5心血管死亡率弱相关。CAD组中CG等位基因亚组5年生存率分别为为92.3%和94.3%,非CAD组中分别为95.7%,98.0%。

研究表明,血管内皮生长因子rs2010963多态性可能与CAD的出现及其长期存活有关,但与其严重程度无关。据目前所知,这是rs2010963 SNPCAD相关死亡之间遗传关联的第一份报告。因此可以考虑将rs2010963 VEGF基因认为是CAD及其结局的遗传风险预测因子。

原始出处:

Samira Kalayi Nia, Shayan Ziaee, et.al. The impact of vascular endothelial growth factor +405 C/G polymorphism on long-term outcome and severity of coronary artery disease.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645572, encodeId=677e16455e2fe, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Thu Dec 07 16:18:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252898, encodeId=4c1f125289819, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517966, encodeId=aed1151e966ab, content=<a href='/topic/show?id=aa2269613cd' target=_blank style='color:#2F92EE;'>#生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69613, encryptionId=aa2269613cd, topicName=生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df311117154, createdName=12499e01m50暂无昵称, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597125, encodeId=b06f159e12563, content=<a href='/topic/show?id=23be895453d' target=_blank style='color:#2F92EE;'>#血管内皮生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89545, encryptionId=23be895453d, topicName=血管内皮生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2a18492798, createdName=qilu_qi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629225, encodeId=65451629225c4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645572, encodeId=677e16455e2fe, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Thu Dec 07 16:18:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252898, encodeId=4c1f125289819, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517966, encodeId=aed1151e966ab, content=<a href='/topic/show?id=aa2269613cd' target=_blank style='color:#2F92EE;'>#生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69613, encryptionId=aa2269613cd, topicName=生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df311117154, createdName=12499e01m50暂无昵称, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597125, encodeId=b06f159e12563, content=<a href='/topic/show?id=23be895453d' target=_blank style='color:#2F92EE;'>#血管内皮生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89545, encryptionId=23be895453d, topicName=血管内皮生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2a18492798, createdName=qilu_qi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629225, encodeId=65451629225c4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645572, encodeId=677e16455e2fe, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Thu Dec 07 16:18:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252898, encodeId=4c1f125289819, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517966, encodeId=aed1151e966ab, content=<a href='/topic/show?id=aa2269613cd' target=_blank style='color:#2F92EE;'>#生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69613, encryptionId=aa2269613cd, topicName=生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df311117154, createdName=12499e01m50暂无昵称, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597125, encodeId=b06f159e12563, content=<a href='/topic/show?id=23be895453d' target=_blank style='color:#2F92EE;'>#血管内皮生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89545, encryptionId=23be895453d, topicName=血管内皮生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2a18492798, createdName=qilu_qi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629225, encodeId=65451629225c4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645572, encodeId=677e16455e2fe, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Thu Dec 07 16:18:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252898, encodeId=4c1f125289819, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517966, encodeId=aed1151e966ab, content=<a href='/topic/show?id=aa2269613cd' target=_blank style='color:#2F92EE;'>#生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69613, encryptionId=aa2269613cd, topicName=生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df311117154, createdName=12499e01m50暂无昵称, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597125, encodeId=b06f159e12563, content=<a href='/topic/show?id=23be895453d' target=_blank style='color:#2F92EE;'>#血管内皮生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89545, encryptionId=23be895453d, topicName=血管内皮生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2a18492798, createdName=qilu_qi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629225, encodeId=65451629225c4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645572, encodeId=677e16455e2fe, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Thu Dec 07 16:18:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252898, encodeId=4c1f125289819, content=<a href='/topic/show?id=463230886b8' target=_blank style='color:#2F92EE;'>#冠状动脉疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30886, encryptionId=463230886b8, topicName=冠状动脉疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517966, encodeId=aed1151e966ab, content=<a href='/topic/show?id=aa2269613cd' target=_blank style='color:#2F92EE;'>#生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69613, encryptionId=aa2269613cd, topicName=生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3df311117154, createdName=12499e01m50暂无昵称, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597125, encodeId=b06f159e12563, content=<a href='/topic/show?id=23be895453d' target=_blank style='color:#2F92EE;'>#血管内皮生长因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89545, encryptionId=23be895453d, topicName=血管内皮生长因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2a18492798, createdName=qilu_qi, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629225, encodeId=65451629225c4, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Wed Jul 26 07:18:00 CST 2017, time=2017-07-26, status=1, ipAttribution=)]
    2017-07-26 xzw120

相关资讯

喜大普奔!新的治疗方法可更好的防止糖尿病患者的视力下降

喜大普奔!新的治疗方法可更好的防止糖尿病患者的视力下降本月早些时候,由美国国家眼科研究所(NEI)资助的研究人员发现雷珠单抗(兰尼单抗)可有效治疗增殖性糖尿病视网膜病变。此发现可以说是40年以来糖尿病视网膜病变治疗的第一次重大进展。糖尿病视网膜病变是造成处于劳动年龄美国人视力下降以及失明的首要原因。其中一个侵袭性阶段称为增殖性糖尿病视网膜病变,通常是由于视网膜附近出现血管异常生长导致。这些新生血管

Nature:抗血管生成药物治疗癌症的局限性

       抗血管生成药物主要是通过影响肿瘤内的血管形成来用于癌症治疗。但这些药物似乎也可能会降低另一些抗癌药物的效率,增强肿瘤的侵袭性。(Nature. 2012 Apr 4;484(7392):44-6)        肿瘤生长依赖于新血管形成以确保持续供给氧气和营养。基于此,临床上常采用抗血管生成药物

Cancer Cell:多梳蛋白4与肝癌生存期密切相关

上海交通大学医学院细胞分化和凋亡教育部重点实验室陈国强教授领衔的课题组科研人员历时6年,在多梳蛋白4(Cbx4)干预肝癌组织新生血管生成研究方面取得突破,相关研究论文日前发表在国际学术刊物《癌细胞》杂志上。专家认为,Cbx4与肝癌病人的生存期密切相关,有望成为临床上判断肝癌预后的指标;同时发现Cbx4通过泛素蛋白修饰调控肝癌的新生血管生成,为肝癌治疗提供新启示。【原文下载】 肝癌的发病率和致死率

Oncologist:贝伐单抗联合化疗可能提高疗效

针对肿瘤新生血管形成或血管生成的治疗手段在癌症治疗中占有重要地位,贝伐单抗等针对血管内皮生长因子(VEGF)的单克隆抗体生物制剂在临床上已被广泛运用。 抗血管生成疗法的基本原理是如果肿瘤获得新的血液供应能力有限,那么它们的生长和转移能力也会受到限制。更多的证据表明,修饰和/或“正常化”不规则的肿瘤血管,减少缺氧可加强肿瘤细胞毒性化疗(CT)的功效。 事实上,对于转移性大肠直肠癌,贝伐单抗联合C

Meta分析:阿瓦斯汀对乳腺癌患者无益

MedSci补充:本荟萃分析表明对转移性乳腺癌来说,抗VEGF治疗,仍然存在争议。对患者的PFS来说,可能是有益的,但对OS,以及QOL尚未发现益处。但是VEGF已被中止用于乳腺癌,因此,本荟萃分析的价值是相对较小的。但是,阿瓦斯汀仍广泛用于治疗其它一些肿瘤的治疗。       针对抗癌药阿瓦斯汀(贝伐单抗)一项的新研究显示,并不能延长

Cell Mol Life Sci:急性髓细胞白血病中VEGF信号

近日,一项最新研究论文阐明了血管内皮生长因子信号(VEGF)在急性髓细胞白血病(AML)中的相关作用。在AML患者骨髓中血管内皮生长因子信号是异常的,其与癌症患者预后较差有关。信号转导通路的改变表现为存在多个自分泌和旁分泌信号通路共同干预。 血管内皮生长因子信号促进急性髓细胞白血病细胞增殖、生存以及抵抗化疗,产生耐药性。此外在急性髓细胞白血病中,血管内皮生长因子信号可以调解血管内皮细胞的旁分泌控

Baidu
map
Baidu
map
Baidu
map